diff --git a/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md b/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md deleted file mode 100644 index 2769f0ed0..000000000 --- a/domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md +++ /dev/null @@ -1,20 +0,0 @@ ---- -type: claim -domain: health -description: "Omada's high-touch program shows 63% of members maintaining or continuing weight loss 12 months after GLP-1 discontinuation, with 0.8% average weight change versus 6-7% regain in unassisted cessation" -confidence: experimental -source: Omada Health internal analysis (n=1,124), presented ObesityWeek 2025, not peer-reviewed -created: 2026-04-13 -title: Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement -agent: vida -scope: causal -sourcer: Omada Health ---- - -# Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement - -The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 benefits revert within 1-2 years of stopping medication, suggesting continuous delivery is required. However, Omada Health's Enhanced GLP-1 Care Track analysis challenges this categorical claim. Among 1,124 members who discontinued GLP-1s, 63% maintained or continued losing weight 12 months post-cessation, with an average weight change of just 0.8% compared to the 6-7% average regain seen in unassisted cessation. This represents a dramatic divergence from expected rebound patterns. - -The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators. - -Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window. diff --git a/entities/health/omada-health.md b/entities/health/omada-health.md deleted file mode 100644 index f1226056a..000000000 --- a/entities/health/omada-health.md +++ /dev/null @@ -1,12 +0,0 @@ -# Omada Health - -**Type:** Digital health company -**Focus:** Employer-sponsored chronic condition management programs -**Key Product:** Enhanced GLP-1 Care Track with behavioral wraparound - -## Overview -Omada Health operates digital health programs for chronic condition management, primarily distributed through employer-sponsored benefits. Their Enhanced GLP-1 Care Track combines medication support with high-touch behavioral interventions including care teams, dose titration education, side effect management, nutrition guidance, exercise specialists, and access barrier navigation. - -## Timeline -- **2025-01-01** — Internal analysis (n=1,124) shows 94% GLP-1 persistence at 12 weeks vs. 42-80% industry range, and 63% of discontinuers maintaining or continuing weight loss 12 months post-cessation -- **2025-10-XX** — Presented post-discontinuation outcomes at ObesityWeek 2025 (peer-reviewed publication pending as of April 2026) \ No newline at end of file diff --git a/inbox/archive/health/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md b/inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md similarity index 98% rename from inbox/archive/health/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md rename to inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md index 5ed2f5038..0fb98f787 100644 --- a/inbox/archive/health/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md +++ b/inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md @@ -7,12 +7,9 @@ date: 2018-09-18 domain: health secondary_domains: [] format: report -status: processed -processed_by: vida -processed_date: 2026-04-13 +status: unprocessed priority: high tags: [uspstf, glp1, policy, obesity, aca-coverage, pharmacotherapy, access-infrastructure] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content diff --git a/inbox/archive/health/2026-04-13-wasden-2026-racial-disparities-glp1-prescribing.md b/inbox/queue/2026-04-13-wasden-2026-racial-disparities-glp1-prescribing.md similarity index 97% rename from inbox/archive/health/2026-04-13-wasden-2026-racial-disparities-glp1-prescribing.md rename to inbox/queue/2026-04-13-wasden-2026-racial-disparities-glp1-prescribing.md index 337b79adb..1e9b6544a 100644 --- a/inbox/archive/health/2026-04-13-wasden-2026-racial-disparities-glp1-prescribing.md +++ b/inbox/queue/2026-04-13-wasden-2026-racial-disparities-glp1-prescribing.md @@ -7,12 +7,9 @@ date: 2026-01-01 domain: health secondary_domains: [] format: article -status: processed -processed_by: vida -processed_date: 2026-04-13 +status: unprocessed priority: high tags: [glp1, racial-disparities, access-equity, medicaid, prescribing-disparities, health-equity] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content